Hexanucleotide repeat expansion in the bi-directionally transcribed C9orf72 gene is the most frequent cause of familial ALS and frontotemporal dementia (FTD). Kramer et al. (2016) report in Science that targeted reduction in the transcription elongation factor SUPT4H1/SUPT5H reduces both sense and antisense repeatcontaining RNAs and their associated neurodegeneration.
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disorder in which premature loss of upper and lower motor neurons leads to fatal paralysis. It is now increasingly recognized that ALS and frontotemporal dementia (FTD), a neurodegenerative disease characterized by behavioral and language changes, belong to a disease continuum that has clinical, pathological, and genetic overlap. In 2011, the strongest genetic link between ALS and FTD was identified to be a GGGGCC hexanucleotide repeat expansion in the C9orf72 gene (DeJesusHernandez et al., 2011; Renton et al., 2011) . Intron 1 of the C9orf72 gene contains a GGGGCC hexanucleotide normally repeated between 2 and 30 times, but patients with C9orf72 mutations carry an allele with an inherited length of hundreds of repeats that further expand somatically in the nervous system to thousands of repeats ( Figure 1A ). Repeat expansion in C9orf72 is the most frequent cause of both inherited ALS and FTD.
The identification of repeat expansion in C9orf72 adds ALS/FTD to the growing list of repeat expansion disorders, which includes Huntington's disease, myotonic dystrophies, Fragile X syndrome, Friedreich's ataxia, and several spinocerebellar ataxias. Three mechanisms have been proposed for how C9orf72 repeat expansions cause disease (to be referred to as C9ALS/FTD): (1) loss of C9orf72 protein function and/or gain of toxicity from repeat-containing RNAs by either (2) sequestration of key RNA-binding proteins into intranuclear RNA foci comprised of repeat RNA or (3) production of aberrant dipeptide repeat (DPR) proteins through repeat-associated non-AUGdependent (RAN) translation that does not require an AUG start codon. To make it more complicated, both sense GGGGCC and antisense CCCCGG repeat-containing RNAs are transcribed from the mutant C9orf72 gene, form independent sense and antisense RNA foci, and those RNAs are translated to produce five different DPR proteins in C9ALS/FTD patients (poly [GA] Loss of C9orf72 function alone seems unlikely to be sufficient to cause ALS/FTD as no missense or truncation mutations have been identified thus far in patients, and in mice neither reduction nor complete ablation of C9orf72 provokes central nervous system (CNS) disease (Jiang et al., 2016; O'Rourke et al., 2016) . Whether C9orf72 loss of function contributes to disease together with gain of toxicity has not been determined. C9orf72 null mice develop disease outside the nervous system, including splenomegaly and increased lymph node size, along with lysosomal deficits and altered immune responses in macrophages and microglia. This latter finding has suggested that C9orf72 loss may provoke neuroinflammation that contributes to C9ALS/ FTD (O'Rourke et al., 2016) . On the other hand, overexpression of repeat-containing RNAs or DPR proteins in various model systems including mice (Chew et al., 2015; Jiang et al., 2016; Liu et al., 2016) produces motor deficits and/or FTD-like behavioral abnormalities.
While the degree to which disease pathogenesis arises from RNA-mediated sequestration of vital RNA-binding proteins or from accumulation of RAN translated proteins has not been determined, therapies that reduce repeat-containing RNAs will target both potential mechanisms. The most advanced of this class of therapies is the use of antisense oligonucleotides (ASOs). These designer DNA drugs are short (18-to 20-mer) single-stranded DNA oligonucleotides that when base paired with a target RNA make that RNA a substrate for degradation by the nearly ubiquitously expressed, nuclearly localized enzyme RNase H. A single dose injection into the cerebral spinal fluid of mice of ASOs targeting sense strand RNAs encoded by a 450 repeat-containing human C9orf72 transgene (1) selectively reduced sense repeat-containing RNAs with minimal effect on mature C9orf72 mRNAs, (2) mitigated the accumulation of sense RNA foci and DPR proteins, and (3) significantly ameliorated age-dependent cognitive and behavioral deficits reminiscent of FTD (Jiang et al., 2016) . ASO-induced reduction in repeat-containing sense strand RNAs had no effect, however, on antisense strand foci or RAN products.
Since sense and antisense transcription of the expanded C9orf72 locus may both contribute to toxicity, an even more attractive therapy would be to bi-directionally reduce C9orf72 transcription. A way to do this with a designer DNAbased ASO has now been proposed (Kramer et al., 2016) through the use of an ASO to reduce the expression of the SUPT4H1/SUPT5H transcriptional elongation factor complex that apparently functions to prevent RNA polymerase II from dissociating from a DNA template when it encounters a complicated secondary structure, including hairpins or quadraplexes predicted to form on repeated domains. This activity was originally identified in yeast using a gene inactivation screen to determine that deletion of the gene encoding a small highly conserved zinc finger protein named Spt4 (the yeast homolog of SUPT4H1) selectively inhibited transcription of long CAG trinucleotide repeats responsible for Huntington's disease (Liu et al., 2012) . Remarkably, although Spt4 deletion reduced transcription of genes containing a lengthy stretch of CTG, CAA, or even long AAA repeats, RNA-seq analysis revealed that the majority of RNAs were unchanged. Subsequently, lowering SUPT4H1 by genetic deletion or ASOs in two different mouse models of Huntington's disease was found to reduce transcription of a CAG repeat expansion allele (without affecting a normal allele), accompanied by reduced mutant polyQ protein production and aggregation, mitigated motor impairment, and prolonged lifespan (Cheng et al., 2015) .
Those earlier efforts have now been extended to C9orf72 expansions by Gitler and colleagues (Kramer et al., 2016) , who identify that eliminating SUPT4H1/ SUPT5H reduces (maximally by 2-fold) bi-directional transcription of hexanucleotide repeat-containing C9orf72 RNAs. They start with yeast expressing either 66 sense (GGGGCC) or 66 antisense (CCCCGG) repeats and find that Spt4 deletion decreases both sense and antisense repeat RNAs. Modulation is repeat length dependent: Spt4 deletion has little effect on expression of alleles with only 2 repeats. Sense and antisense RNA foci accumulation from transcription of long hexanucleotide repeats was almost completely blocked by Spt4 depletion. Robust poly(GP) DPR protein accumulation from RAN translation in yeast expressing high levels of 40 GGGGCC repeats was reduced to 25% following Spt4 depletion.
RNA interference (RNAi) to knockdown Spt4 to 10% of normal level was also shown to reduce RNA foci, DPR accumulation, and toxicity in C. elegans expressing a 66 repeat gene in neurons. Conversely, toxicity in those worms was enhanced by expression of the mammalian SUPT4H1 homolog. Similar modulation of eye toxicity was observed in Drosophila expressing 6, 29 or 49 sense GGGGCC repeats. Reducing Spt4 (to 50%) with RNAi partially suppressed the degenerative phenotype in flies expressing 49 GGGGCC repeats and completely suppressed retinal thinning in flies expressing 29 GGGGCC repeats. Furthermore, reducing Spt4 expression increased the lifespan of adult flies ubiquitously expressing 49 GGGGCC repeats.
The repeat length in the nervous systems of C9ALS/FTD patients is much longer than the short repeats used in these test systems. To validate that SUPT4H1/SUPT5H act to transcriptionally elongate longer repeats, small interfering RNAs were used to reduce levels of either or both in human C9ALS patient fibroblasts. Suppression by 80%-90% of either or both genes reduced sense and antisense repeat-containing RNAs by at most 50% and reduced poly(GP) proteins by 60%-80% (Kramer et al., 2016) . In contrast, use of an ASO to target GGGGCC repeat containing RNAs more effectively reduced sense strand RNA foci (by >80%) and inhibited poly(GP) accumulation almost completely, but left antisense RNA foci unaffected (Kramer et al., 2016) . Reducing SUPT4H1 in pluripotent stem cell-derived cortical neurons from C9ALS patients modestly reduced (by 30%) the amount of sense repeatcontaining RNAs and poly(GP). Thus, SUPT4H1 or SUPT5H are important new targets for C9ALS/FTD therapy development, as individually targeting either can bi-directionally reduce transcription of both sense and antisense C9orf72 repeats, leading to the corresponding reduction of multiple C9ALS/FTD pathologies.
It has now been a decade since Smith et al. (2006) pioneered the idea of ASO infusion into the nervous system as therapy for human neurodegenerative disease. The founding example was ALS therapy for inherited disease caused by dominant mutation in the gene encoding superoxide dismutase (SOD1). ASO infusion was found to lower mutant SOD1 synthesis and double survival after disease onset (Smith et al., 2006) . Subsequently, infusion of ASOs into the cerebral spinal fluid at the bottom of the spinal cord was demonstrated to produce dose-dependent RNase H-mediated target RNA degradation throughout the non-human primate nervous system, with single dose injections providing durable target reduction that continued for 3 months (Kordasiewicz et al., 2012) . ASO infusion to lower huntingtin RNAs carrying CAG expansions produced partial disease reversal in two Huntington's disease model mice and prevented further loss of brain mass in the most aggressive and highly used R6/2 model (Kordasiewicz et al., 2012) . These efforts supported initiation of clinical trials currently underway with ASOs for SOD1-linked ALS and Huntington's disease and a successful Phase III trial in spinal muscular atrophy (SMA), which concluded in August 2016 using ASO infusion to restore SMN synthesis by ASOmediated correction of the splicing of the SMN2 gene. d 'Ydewalle et al. (2016) further show that ASOs targeting a long non-coding RNA to transcriptionally activate SMN2 can be combined with SMN2 splicing modification to ameliorate SMA, demonstrating the promise of combinational ASOs for treatment of neurological disorders.
For ALS/FTD from C9orf72 expansion, ASOs targeting sense repeat-containing C9orf72 RNAs can decrease sense RNA foci and DPR proteins in patient derived cells (Donnelly et al., 2013; Lagier-Tourenne et al., 2013; Sareen et al., 2013) . Similarly, ASO infusion can ameliorate both the RNA foci and DPR pathologies in transgenic mice expressing a C9orf72 transgene with 450 repeats and can prevent age-dependent, FTD-like cognitive and behavioral deficits (Jiang et al., 2016) . Although the relative contributions to disease of sense and antisense derived RNAs are not established, ASOs targeting sense repeat-containing RNAs (without affecting antisense RNA foci) are sufficient to mitigate behavioral deficits. Thus, targeting sense repeats definitely has beneficial effects. Whether targeting antisense repeats by ASOs will have additional benefits has not been determined. Nevertheless, the discovery by Gitler's team has enabled a potentially more comprehensive approach in which injection of a single ASO targeting the RNAs encoding either SUPT4H1 or SUPT5H would bi-directionally suppress C9orf72 RNA transcription, RNA foci, and DPR pathologies. Strong support for the broad potential of ASO targeting of SUPT4H1 for repeat expansion diseases has come from expanded allele-specific reduction in huntingtin mRNA expression in mouse models of Huntington's disease (Cheng et al., 2015) . That said, there are two concerns for SUPT4H1 (or SUPT5H) as therapeutic targets.
First, both SUPT4H1 and SUPT5H affect expression of multiple genes. Indeed, while deletion of one copy of SUPT4H1 did not lead to any overt phenotype in mice up to 18 months of age, SUPT4H1 is an essential gene whose absence produces embryonic lethality (Cheng et al., 2015) . Perhaps more importantly, reducing SUPT4H1 to <10% of its normal level in human fibroblasts also altered the expression of >300 genes, 46 of which were changed by >3-fold (Kramer et al., 2016) .
Second, the maximum effect from SUPT4H1/SUPT5H reduction appears to produce a 2-fold reduction in C9orf72 sense and antisense repeat RNAs, with siRNA-mediated lowering of SUPT4H1/ SUPT5H to <10% its initial level producing only 50% reduction of repeat containing RNAs and RNA foci in human C9orf72 expansion fibroblasts. This contrasts with ASO treatment targeting the sense strand C9orf72 intron adjacent to the repeat expansion, which in a dosedependent manner lower or almost eliminate sense strand repeat-containing RNAs, sense RNA foci, and poly(GP) accumulation both in human fibroblasts (Lagier-Tourenne et al., 2013; Kramer et al., 2016) and in the nervous system of transgenic mice (Jiang et al., 2016) .
A key goal now needed for therapy development for SUPT4H1/SUPT5H is to determine the benefit/risk profile by assessing the degree of suppression of C9orf72 RNA foci, DPR, and disease development that can be achieved by ASO-mediated reduction in SUPT4H1/ SUPT5H in transgenic mice overexpressing C9orf72 repeats (Jiang et al., 2016; Liu et al., 2016) .
